OncoMatch/Clinical Trials/NCT06613841
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Is NCT06613841 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Fluciclovine F18 for glioblastoma.
Treatment: Fluciclovine F18 — * To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hospital of the University of Pennsylvania · Philadelphia, Pennsylvania
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify